Additional Hetero Ring Containing Patents (Class 540/222)
  • Patent number: 9499566
    Abstract: The present invention relates to an improved process for oxidizing 3-hydroxy-methyl-cephem derivatives to the corresponding 3-formyl-cephem derivatives. In particular this oxidation process is for the preparation of 7-[2-(5-amino-[1,2,4]thia-diazol-3-yl)-2-hydroxyimino-acetylamino]-3-formyl-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid derivatives of formula (I) using a combination of a hypervalent iodine oxidizing agent of the type 10-I-3 such as bis(acetoxy)iodo-benzene (BAIB) and a catalyst such as 2,2,6,6-tetramethyl-1-piperidinyloxy (TEMPO). These compounds of formula (I) are intermediates in the synthesis of ceftobiprole.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: November 22, 2016
    Assignee: Basilea Pharmaceutica International
    Inventor: Ivan Joseph Maria Vervest
  • Patent number: 9139597
    Abstract: The present invention relates to a method for the production of organic compounds, in particular sodium (6R,7R)-7-[(Z)-2-(5-amino-[1,2,4]thiadiazol-3-yl)-2-hydroxyimino-acetylamino]-8-oxo-3-[(E)-(R)-1?-(5-methyl-2-oxo-[1,3]-dioxol-4-ylmethoxycarbonyl)-2-oxo-[1,3?]bipyrrolidinyl-3-ylidenemethyl]-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylate (ceftobiprole medocaril), and compounds of the general formula (1) and of the general formula (2), the compounds themselves and intermediates in the production according to the invention.
    Type: Grant
    Filed: May 25, 2010
    Date of Patent: September 22, 2015
    Assignee: SANDOZ AG
    Inventors: Peter Kremminger, Johannes Ludescher, Hubert Sturm
  • Patent number: 9125837
    Abstract: The present invention provides a process for producing silylated pullulan, which features reacting pullulan with N,O-bistrimethylsilylacetamide by using, as a reaction medium, only one of N-methyl-2-pyrrolidone and N-ethyl-2-pyrrolidone or a mixed solvent of both of them. Compared with conventional processes, the process according to the present invention can produce high-purity silylated pullulan simply, easily and efficiency.
    Type: Grant
    Filed: March 30, 2007
    Date of Patent: September 8, 2015
    Assignee: DAINICHISEIKA COLOR & CHEMICALS MFG. CO., LTD.
    Inventors: Masato Izume, Takahiro Fukuhara, Makoto Niwa, Takanori Sannan, Shinya Tsuchida, Nobuyuki Kobayashi
  • Patent number: 9096610
    Abstract: The present invention relates to a method for the production of organic compounds, in particular sodium (6R,7R)-7-[(Z)-2-(5-amino-[1,2,4]thiadiazol-3-yl)-2-hydroxyimino-acetylamino]-8-oxo-3-[(E)-(R)-1?-(5-methyl-2-oxo-[1,3]-dioxol-4-ylmethoxycarbonyl)-2-oxo-[1,3?]bipyrrolidinyl-3-ylidenemethyl]-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylate (ceftobiprole medocaril), and compounds of the general formula (1) and of the general formula (2), the compounds themselves and intermediates in the production according to the invention.
    Type: Grant
    Filed: May 25, 2010
    Date of Patent: August 4, 2015
    Assignee: SANDOZ AG
    Inventors: Peter Kremminger, Johannes Ludescher, Hubert Sturm
  • Patent number: 9006421
    Abstract: Provided herein is a method for the synthesis of cephalosporin antibiotic compounds comprising the conversion of a protected 7-amino group into a 7-carboxamide moiety in a single step.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: April 14, 2015
    Assignee: Cubist Pharmaceuticals, Inc.
    Inventors: Jan-Ji Lai, Pradip M. Pathare, Laxma Kolla, Adrien F. Soret
  • Publication number: 20150011524
    Abstract: Broad spectrum beta-lactamase inhibitors. Certain inhibitors also exhibit potent antibiotic activity in addition to beta-lactamase inhibition. Compounds of the invention are designed such that on cleavage of the beta-lactam ring reactive moieties are generated which can inactivate beta-lactamase. Also provided are methods of making beta-lactamase inhibitors and beta-lactam antibiotics exhibiting such inhibition. Additionally provided are pharmaceutical compositions for treatment or prevention of bacterial infections and methods of treatment of such infections.
    Type: Application
    Filed: September 19, 2014
    Publication date: January 8, 2015
    Inventors: Larry SUTTON, Sophia YU
  • Patent number: 8883772
    Abstract: Broad spectrum beta-lactamase inhibitors. Certain inhibitors also exhibit potent antibiotic activity in addition to beta-lactamase inhibition. Compounds of the invention are designed such that on cleavage of the beta-lactam ring reactive moieties are generated which can inactivate beta-lactamase. Compounds of the invention include those of formula: and pharmacologically acceptable salts thereof where variables Z, Y, M, y, n, R, R4, R5, R1 and R2 are as defined in the specification. M most generally represents a chemical moiety which is in conjugation with the nitrogen of the core beta-lactam ring system of the compound, such that one or more reactive species, e.g., electrophilic or nucleophilic sites are generated on modification of M which is initiated by cleavage of the beta-lactam ring. Also provided are methods of making beta-lactamase inhibitors and beta-lactam antibiotics exhibiting such inhibition.
    Type: Grant
    Filed: October 9, 2008
    Date of Patent: November 11, 2014
    Assignee: Sopharmia, Inc.
    Inventors: Larry Sutton, Sophia Yu
  • Patent number: 8865697
    Abstract: A solid DMSO solvate of a compound of formula (I) is described, which is a useful intermediate for preparing the broad spectrum antibiotics Ceftobiprole and Ceftobiprole Medocaril.
    Type: Grant
    Filed: April 14, 2009
    Date of Patent: October 21, 2014
    Assignee: Basilea Pharmaceutica AG
    Inventors: Marco Alpegiani, Walter Cabri, Markus Heubes, Davide Longoni, Michael Schleimer
  • Patent number: 8865891
    Abstract: The present invention relates to compounds that are substrates for an enzyme, and upon reaction with the enzyme provide a detectable response, such as an optically detectable response. In particular, the compounds have utility in detecting the presence of a ?-lactamase in a sample. In addition to the compounds, methods are disclosed for analyzing a sample for the presence of a ?-lactamase, for example, as an indicator of expression of a nucleic acid sequence including a sequence coding for a ?-lactamase. Kits are disclosed that include the disclosed compounds and additional components, for example, cells, antibodies, a ?-lactamase or instructions for using the components in an assay.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: October 21, 2014
    Assignee: Life Technologies Corporation
    Inventors: Schuyler Corry, William Downey, Brian Filanoski, Kyle Gee, Lawrence Greenfield, James Hirsch, Iain Johnson, Aleksey Rukavishnikov
  • Publication number: 20140274958
    Abstract: Provided herein is a method for the synthesis of cephalosporin antibiotic compounds comprising the conversion of a protected 7-amino group into a 7-carboxamide moiety in a single step.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Inventors: Jan-Ji Lai, Pradip M. Pathare, Laxma Kolla, Adrien F. Soret
  • Publication number: 20140274999
    Abstract: Provided herein is a method for the synthesis of cephalosporin antibiotic compounds comprising the conversion of a protected 7-amino group into a 7-carboxamide moiety in a single step.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Inventors: Jan-Ji Lai, Pradip M. Pathare, Laxma Kolla, Adrien F. Soret
  • Publication number: 20140274997
    Abstract: Pharmaceutical compositions including a cephalosporin disclosed herein as having the structure of formula (III).
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Inventors: Jianxun Zhou, Nicole Miller Damour, Yanmei Lan, Jonathan Cam Ly, Joseph Terracciano
  • Publication number: 20140256697
    Abstract: A compound represented by formula (I) or a pharmaceutically acceptable salt thereof wherein A represents a group represented by one of formulae (i)-(iii); B represents a group represented by formula (v) or (vi); and E represents a substituted or unsubstituted heterocyclic group having a cationic nitrogen atom.
    Type: Application
    Filed: October 3, 2012
    Publication date: September 11, 2014
    Inventors: Kenji Yamawaki, Masayuki Sano, Jun Sato
  • Publication number: 20140249126
    Abstract: The present invention relates to cephalosporin antibacterial compounds of Formula (I): or corresponding pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, compound preparation and treatment methods for bacterial infections, especially those caused by gram-negative bacteria.
    Type: Application
    Filed: October 4, 2012
    Publication date: September 4, 2014
    Inventors: Xiangmin Liao, Neil David Pearson, Israil Pendrak, Masayuki Sano
  • Publication number: 20140221331
    Abstract: The present invention relates generally to methods and compounds for regulating the release of nitric oxide in the vicinity of biofilm-forming microorganisms to regulate programmed cell death in the microorganisms and thereby promote dispersal of microorganism from biofilms and/or inhibit biofilm formation or development. More particularly, the invention relates to the use of compounds to provide spatial and temporal control over nitric oxide release.
    Type: Application
    Filed: May 16, 2012
    Publication date: August 7, 2014
    Applicants: UNIVERSITY OF WOLLONGONG, NEWSOUTH INNOVATIONS PTY LIMITED
    Inventors: Nicolas Barraud, Bharat Gangadhar Kardak, Michael John Kelso, Staffan Kjelleberg, Scott Rice
  • Publication number: 20140079647
    Abstract: The invention features pharmaceutically acceptable salts of cefdinir, including primary, secondary, and tertiary amine salts of cefdinir, and preparation methods, and pharmaceutical compositions including cefdinir. The invention also features water dispersible pharmaceutical dosage forms including cefdinir as active agent and methods for preparing the dosages. The invention also features tablet forms of cefixime characterized in that the tablets are in effervescent form. The invention also features the process for preparing effervescent tablet forms with cefdinir as active agents and pharmaceutical formulations obtained by the process.
    Type: Application
    Filed: November 25, 2013
    Publication date: March 20, 2014
    Inventor: Mahmut BILGIC
  • Publication number: 20140051625
    Abstract: The present invention provides novel bisphosphonate conjugates, pharmaceutical compositions comprising bisphosphonate conjugates and methods of using such analogs in the treatment of bone cancer, bone-related diseases, bone infection, bone inflammation, and diseases of the soft tissues surrounding bones.
    Type: Application
    Filed: October 25, 2013
    Publication date: February 20, 2014
    Applicant: MBC Pharma, Inc.
    Inventors: Alexander Karpeisky, Shawn Patrick Zinnen
  • Patent number: 8614315
    Abstract: The invention features pharmaceutically acceptable salts of cefdinir, including primary, secondary, and tertiary amine salts of cefdinir, and preparation methods, and pharmaceutical compositions including cefdinir. The invention also features water dispersible pharmaceutical dosage forms including cefdinir as active agent and methods for preparing the dosages. The invention also features tablet forms of cefixime characterized in that the tablets are in effervescent form. The invention also features the process for preparing effervescent tablet forms with cefdinir as active agents and pharmaceutical formulations obtained by the process.
    Type: Grant
    Filed: June 25, 2012
    Date of Patent: December 24, 2013
    Inventor: Mahmut Bilgic
  • Patent number: 8575144
    Abstract: Inhibitors of the enzyme beta-lactamase are provided comprising compounds of formula (II) wherein R1 or R2 is a pyridyl group and R5 is a group of formula The compounds are adapted to inhibit beta-lactamase as produced by beta-lactam resistant bacterial strains. Methods of treatment of beta-lactam resistant bacterial infections in patients are provided.
    Type: Grant
    Filed: September 27, 2012
    Date of Patent: November 5, 2013
    Assignee: Southern Methodist University
    Inventors: John D. Buynak, Anjaneyulu Sheri, Sundar Ram Reddy Pagadala
  • Patent number: 8557978
    Abstract: This invention provides cross-linked glycopeptide-cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using such compounds; and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: September 21, 2011
    Date of Patent: October 15, 2013
    Assignee: Theravance, Inc.
    Inventor: Daniel D. Long
  • Publication number: 20130178455
    Abstract: The present invention relates to novel cephalosporin derivatives represented by Chemical Formula 1. Wherein, X, Y, L, R1, and R2 are as same as defined in the description of the invention. The present invention also relates to pharmaceutical antibiotic compositions comprising a novel celphalosporin derivative represented by Chemical Formula 1, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient. According to the present invention, novel cephalosporin derivatives, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient for the broad spectrum of antibiotic resistant, low toxicity, particularly in Gram-negative bacteria, which can be useful with strong antimicrobial activity.
    Type: Application
    Filed: November 30, 2012
    Publication date: July 11, 2013
    Applicant: LEGOCHEM BIOSCIENCES, INC
    Inventor: Legochem Biosciences, Inc.
  • Publication number: 20130131006
    Abstract: The present invention relates to a method for inhibiting the induction of cell death by inhibiting the synthesis or secretion of AGE-albumin in cells of the mononuclear phagocyte system, to an AGE-albumin synthesis inhibitor, and to a pharmaceutical composition comprising the AGE-albumin synthesis inhibitor for preventing or treating degenerative disease and autoimmune disease. The AGE-albumin of the present invention is synthesized and secreted in human microglia or human macrophages in an Alzheimer's model, stroke model, Parkinson's disease model and rheumatoid arthritis model. The AGE-albumin synthesis and secretion are caused by oxidative stress. The expression of RAGE increases in first-order human neurons or cartilage cells to which AGE-albumin is administered, whereupon a MAPK signaling pathway is activated and the expression of Bax increases to induce an increase in calcium in mitochondria, thus finally inducing cell death.
    Type: Application
    Filed: April 28, 2011
    Publication date: May 23, 2013
    Applicant: Gachon University of Industry-Academic Cooperation Foundation
    Inventors: Bong Hee Lee, Kyung Hee Byun
  • Publication number: 20130102583
    Abstract: A compound of the formula: wherein X is —N?, —CH?, or the like; W is —CH2— or the like; U is —S— or the like; R1 and R2 are each independently hydrogen, halogen, optionally substituted lower alkyl, or the like; R3 is hydrogen or the like; each R4 is independently hydrogen, halogen, or the like; m is an integer from 0 to 2; Q is a single bond, or the like; G is —C(?O)—, or the like; D is a single bond, —NH—, or the like; and E is a cyclic quaternary ammonium group, or an ester, a protected compound at the amino on the ring in the 7-side chain, a pharmaceutically acceptable salt, or a solvate thereof.
    Type: Application
    Filed: April 4, 2011
    Publication date: April 25, 2013
    Applicant: SHIONOGI & CO., LTD.
    Inventors: Shinya Hisakawa, Yasushi Hasegawa, Toshiaki Aoki, Hiroki Kusano, Masayuki Sano, Jun Sato, Kenji Yamawaki
  • Publication number: 20130096299
    Abstract: Provided is a cephem compound which has a wide antimicrobial spectrum, and in particular exhibit potent antimicrobial activity against beta-lactamase producing Gram negative bacteria, and pharmaceutical composition comprising the same. A Compound of the formula (I): wherein W and U are as defined in the specification; R1 is as defined in the specification; R2A and R2B are as defined in the specification, provided that R2A and R2B are not taken together to form an optionally substituted oxime group when R1 is aminothiazole or aminothiadiazole optionally protected at the amino group; ring A is a benzene ring or a 6-membered aromatic heterocyclic group having 1-3 nitrogen atoms; R3 is a hydrogen atom, —OCH3 or —NH—CH(?O); k is an integer from 0 to 2; R4 is as defined in the specification; and D and E are as defined in accordance with a) or b) described in the specification.
    Type: Application
    Filed: April 27, 2011
    Publication date: April 18, 2013
    Applicant: SHIONOGI & CO., LTD.
    Inventors: Hiroki Kusano, Kenji Yamawaki
  • Publication number: 20130090470
    Abstract: The present invention relates to compounds that are substrates for an enzyme, and upon reaction with the enzyme provide a detectable response, such as an optically detectable response. In particular, the compounds have utility in detecting the presence of a ?-lactamase in a sample. In addition to the compounds, methods are disclosed for analyzing a sample for the presence of a ?-lactmase, for example, as an indicator of expression of a nucleic acid sequence including a sequence coding for a ?-lactmase. Kits are disclosed that include the disclosed compounds and additional components, for example, cells, antibodies, a ?-lactmase or instructions for using the components in an assay.
    Type: Application
    Filed: September 13, 2012
    Publication date: April 11, 2013
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: Schuyler CORRY, William Downey, Brian Filanoski, Kyle Gee, Lawrence Greenfield, James Hirsch, Iain Johnson, Aleksey Rukavishnikov
  • Publication number: 20130066065
    Abstract: The present invention relates to an improved process for oxidizing 3-hydroxy-methyl-cephem derivatives to the corresponding 3-formyl-cephem derivatives. In particular this oxidation process is for the preparation of 7-[2-(5-amino-[1,2,4]thia-diazol-3-yl)-2-hydroxyimino-acetylamino]-3-formyl-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid derivatives of formula (I) using a combination of a hypervalent iodine oxidizing agent of the type 10-I-3 such as bis(acetoxy)iodo-benzene (BAIB) and a catalyst such as 2,2,6,6-tetramethyl-1-piperidinyloxy (TEMPO). These compounds of formula (I) are intermediates in the synthesis of ceftobiprole.
    Type: Application
    Filed: May 9, 2011
    Publication date: March 14, 2013
    Applicant: Basilea Pharmaceutica International
    Inventor: Ivan Joseph Maria Vervest
  • Publication number: 20130017156
    Abstract: The invention features pharmaceutically acceptable salts of cefdinir, including primary, secondary, and tertiary amine salts of cefdinir, and preparation methods, and pharmaceutical compositions including cefdinir. The invention also features water dispersible pharmaceutical dosage forms including cefdinir as active agent and methods for preparing the dosages. The invention also features tablet forms of cefixime characterized in that the tablets are in effervescent form. The invention also features the process for preparing effervescent tablet forms with cefdinir as active agents and pharmaceutical formulations obtained by the process.
    Type: Application
    Filed: June 25, 2012
    Publication date: January 17, 2013
    Inventor: Mahmut Bilgic
  • Patent number: 8329895
    Abstract: A compound represented by Formula I, wherein M represents Na+, K+, NH4+, or Cs+; and 1) when Y represents SO42?: when m=1, then n=1; and when m=0.5, then n=1.5; and 2) when Y represents PO43?, when m=1, then n=2. The compound has good solubility and high bioavailability and can be formulated into oral pharmaceutical preparations and pharmaceutical preparations for injections.
    Type: Grant
    Filed: June 30, 2011
    Date of Patent: December 11, 2012
    Assignees: Zhejiang Adamerck Biopharmlabs Inc., Zhejiang Yongning Pharma Co., Ltd.
    Inventors: Youmao Qi, Fengqi Ye, Qing Jie, Yingbei Qi, Fengmin Zhang, Baochun Yu, Tianjian Ye, Meiping Yu
  • Patent number: 8329684
    Abstract: The present invention relates to novel cephalosporin derivatives represented by Chemical Formula 1. Wherein, X, Y, L, R1, and R2 are as same as defined in the description of the invention. The present invention also relates to pharmaceutical antibiotic compositions comprising a novel celphalosporin derivative represented by Chemical Formula 1, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient. Compounds of the present invention are effective ingredients for the broad spectrum of antibiotic resistance, exhibit low toxicity, particularly in Gram-negative bacteria, which can be useful with strong antimicrobial activity.
    Type: Grant
    Filed: May 8, 2012
    Date of Patent: December 11, 2012
    Assignee: Legochem Biosciences, Inc.
    Inventors: Young Lag Cho, Joung Yul Yun, Sang Eun Chae, Chul Soon Park, Hyang Sook Lee, Kyu Man Oh, Hye Jin Kang, Dae Hyuck Kang, Young Jae Yang, Hyun Jin Kwon, Tae Kyo Park, Sung Ho Woo, Young Zu Kim
  • Publication number: 20120264727
    Abstract: The present invention relates to novel cephalosporin derivatives represented by Chemical Formula 1. Wherein, X, Y, L, R1, and R2 are as same as defined in the description of the invention. The present invention also relates to pharmaceutical antibiotic compositions comprising a novel celphalosporin derivative represented by Chemical Formula 1, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient. According to the present invention, novel cephalosporin derivatives, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient for the broad spectrum of antibiotic resistant, low toxicity, particularly in Gram-negative bacteria, which can be useful with strong antimicrobial activity.
    Type: Application
    Filed: May 8, 2012
    Publication date: October 18, 2012
    Applicant: Legochem Biosciences, Inc.
    Inventors: Young Lag CHO, Hye Jin HEO, Kyu Man OH, Hyang Sook LEE, Chul Soon PARK, Sang Eun CHAE, Joung Yul YUN, Hyun Jin KWON, Young Jae YANG, Dae Hyuck KANG, Yong Zu KIM, Sung Ho WOO, Tae Kyo PARK
  • Publication number: 20120116070
    Abstract: The present invention relates to a method for the production of organic compounds, in particular sodium (6R,7R)-7-[(Z)-2-(5-amino-[1,2,4]thiadiazol-3-yl)-2-hydroxyimino-acetylamino]-8-oxo-3-[(E)-(R)-1?-(5-methyl-2-oxo-[1,3]-dioxol-4-ylmethoxycarbonyl)-2-oxo-[1,3?]bipyrrolidinyl-3-ylidenemethyl]-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylate (ceftobiprole medocaril), and compounds of the general formula (1) and of the general formula (2), the compounds themselves and intermediates in the production according to the invention.
    Type: Application
    Filed: May 25, 2010
    Publication date: May 10, 2012
    Applicant: SANDOZ AG
    Inventors: Peter Kremminger, Johannes Ludescher, Hubert Sturm
  • Publication number: 20120108807
    Abstract: The present invention relates to a method for the production of organic compounds, in particular sodium (6R,7R)-7-[(Z)-2-(5-amino-[1,2,4]thiadiazol-3-yl)-2-hydroxyimino-acetylamino]-8-oxo-3-[(E)-(R)-1?-(5-methyl-2-oxo-[1,3]-dioxol-4-ylmethoxycarbonyl)-2-oxo-[1,3?]bipyrrolidinyl-3-ylidenemethyl]-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylate (ceftobiprole medocaril), and compounds of the general formula (1) and of the general formula (2), the compounds themselves and intermediates in the production according to the invention.
    Type: Application
    Filed: May 25, 2010
    Publication date: May 3, 2012
    Applicant: SANDOZ AG
    Inventors: Peter Kremminger, Johannes Ludescher, Hubert Sturm
  • Patent number: 8093377
    Abstract: The present invention relates to cephalosporin of formula (I) in crystalline form. The compound of formula (I) in crystalline form is useful as antibiotics having potent and broad antibacterial activity; especially against methicillin resistant Staphylococci (MRSA) and Pseudomonas aeruginosa.
    Type: Grant
    Filed: April 1, 2009
    Date of Patent: January 10, 2012
    Assignee: Basilea Pharmaceutica AG
    Inventor: Joerg Berghausen
  • Patent number: 8071761
    Abstract: Substrates for ?-lactamase of the general formula I in which one of X and Y is a fluorescent donor moiety and the other is a quencher (which may or may not re-emit); R? is selected from the group consisting of H, lower (i.e., alkyl of 1 to about 5 carbon atoms) and (CH2)nOH, in which n is 0 or an integer from 1 to 5; R? is selected from the group consisting of H, physiologically acceptable metal and ammonium cations, —CHR2OCO(CH2)nCH3, —CHR2OCOC (CH3)3, acylthiomethyl, acyloxy-alpha-benzyl, delta-butyrolactonyl, methoxycarbonyloxymethyl, phenyl, methylsulphinylmethyl, beta-morpholinoethyl, dialkylaminoethyl, acyloxyalkyl, dialkylaminocarbonyloxymethyl and aliphatic, in which R2 is selected from the group consisting of H and lower alkyl; A is selected from the group consisting of S, O, SO, SO2 and CH2; and Z? and Z? are linkers for the fluorescent donor and quencher moieties.
    Type: Grant
    Filed: November 29, 2006
    Date of Patent: December 6, 2011
    Assignee: The Regents of the University of California
    Inventors: Roger Y. Tsien, Gregor Zlokarnik
  • Publication number: 20110269689
    Abstract: High penetration compositions (HPC) of a parent compound, which are capable of crossing biological barriers with high penetration efficiency. The HPCs are capable of being converted to parent drugs or parent drug-related compounds such as metabolites after crossing one or more biological barriers and thus can render treatments for the conditions that the parent drugs or parent drug-related compounds can. Additionally, the HPCs are capable of reaching areas that their parent drugs or parent drug-related compounds may not be able to access or to render a sufficient concentration at the target areas HPCs of NSAIA, for example, have demonstrated indications such as treating hair loss. A HPC can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.
    Type: Application
    Filed: December 4, 2009
    Publication date: November 3, 2011
    Inventor: Chongxi Yu
  • Patent number: 8044195
    Abstract: This invention provides cross-linked glycopeptide—cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using such compounds; and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: April 13, 2010
    Date of Patent: October 25, 2011
    Assignee: Theravance, Inc.
    Inventor: Daniel D. Long
  • Patent number: 8008478
    Abstract: The present invention provides an improved process for the preparation of Cefixime of formula (I), a cephalosporine antibiotic with an improved quality in regard to color and solubility. This process includes: (i) reaction of 7-?-(4-chloro-2-alkoxycarbonyl methoxyimino-3-oxobutyromido)-3-cephem-4-carboxylic acid (V) with thiourea at pH 5.0 to 6.0 at temperature 25-40° C. in water, (ii) carbon treatment to the reaction mixture in presence of sodium dithionite or ethylenediaminetetraacetic acid (EDTA) followed by filtration, (iii) acidification of the filtrate obtained in step (ii) to pH 2.0 to 3.0 with acid at 50-80° C. to give cefixime ester (IV) (iv) alkaline hydrolysis of cefixime ester of formula (IV) in water followed by acidification to pH 5.0 to 6.0, (v) precipitation of cefixime (I) by adding ketone solvent followed by acidification to pH 2.0 to 3 and (vi) isolation of solid.
    Type: Grant
    Filed: December 19, 2005
    Date of Patent: August 30, 2011
    Assignee: Lupin Limited
    Inventors: Om Dutt Tyagi, Dnyandeo Ragho Rane, Sanjay Mahajan, Yuvraj Atmaram Chavan
  • Publication number: 20110190254
    Abstract: The present invention provides Cephem compounds which have a wide antimicrobial spectrum and have potent antimicrobial activity against beta-lactamase producing Gram negative bacteria as follows: A compound of the formula: wherein, X is N, CH or C—Cl; T is S or the like; A and G are lower alkylene or the like; B is a single bond or the like; D is a single bond, —NR7—, —CO—, —CO—NR7—, —NR7—CO—, —NR7—CO—NR7—, or the like; E is optionally substituted lower alkylene; F is a single bond or optionally substituted phenylene; R3, R4, R5 and R6 each is independently hydrogen, halogene, nitrile, or the like; or an ester, a compound protected at the amino on the ring in the 7-side chain, a pharmaceutically acceptable salt, or a solvate thereof.
    Type: Application
    Filed: October 27, 2009
    Publication date: August 4, 2011
    Applicant: SHIONOGI & CO., LTD.
    Inventors: Yasuhiro Nishitani, Kenji Yamawaki, Yusuke Takeoka, Hideki Sugimoto, Shinya Hisakawa, Toshiaki Aoki
  • Publication number: 20110137026
    Abstract: A solid DMSO solvate of a compound of formula (I) is described, which is a useful intermediate for preparing the broad spectrum antibiotics Ceftobiprole and Ceftobiprole Medocaril.
    Type: Application
    Filed: April 14, 2009
    Publication date: June 9, 2011
    Applicant: BASILEA PHARMACEUTICA AG
    Inventors: Marco Alpegiani, Walter Cabri, Markus Heubes, Davide Longoni, Michael Schleimer
  • Publication number: 20110020240
    Abstract: Provided herein are imaging methods for detecting, diagnosing and imaging pathogenic bacteria or a pathophysiological condition associated therewith using fluorogenic substrates for bacterial enzymes. Fluorescent, luminescent or colorimetric signals emitted by substrates or enzyme products in the presence of the bacteria are compared to controls to detect and locate the pathogenic bacteria. Provided is a method for screening therapeutic agents to treat the pathophysiological conditions by measuring a signal emitted from the fluorogenic substrates or products in the presence and absence of the potential therapeutic agent. In addition, a diagnostic method for detecting a mycobacterial infection in a subject by contacting biological samples with a fluorogenic substrate and imaging for signals emitted from a mycobacterial beta-lactamase product.
    Type: Application
    Filed: June 4, 2010
    Publication date: January 27, 2011
    Inventors: Jeffrey D. Cirillo, James C. Sacchettini, Jianghong Rao, Hexin Xie
  • Patent number: 7868147
    Abstract: A fluorescent probe which is represented by the following formula (I): (wherein, R1 represents a monovalent substituent other than hydrogen atom, carboxy group, or sulfo group; R2 represents hydrogen atom, or a monovalent substituent; R3 and R4 each independently represents hydrogen atom or a halogen atom; and R5 represents a monovalent group which is cleaved by contact with a measuring object, provided that a combination of R1 and R2 is selected so that the oxidation potential of the benzene ring to which they bind makes (1) the compound represented by the formula (I) substantially no fluorescent before the cleavage, and (2) a compound after the cleavage, which is derived from the compound represented by the formula (I), substantially highly fluorescent after the cleavage).
    Type: Grant
    Filed: September 3, 2004
    Date of Patent: January 11, 2011
    Assignees: Sekisui Medical Co., Ltd.
    Inventors: Tetsuo Nagano, Mako Kamiya, Yasuteru Urano
  • Patent number: 7847093
    Abstract: This invention provides processes for preparing cefepime, including crystalline intermediates of Formula V.
    Type: Grant
    Filed: April 15, 2004
    Date of Patent: December 7, 2010
    Assignee: Sandoz AG
    Inventors: Johannes Ludescher, Hubert Sturm, Siegfried Wolf
  • Patent number: 7825241
    Abstract: 7-[2-(2-aminothiazol-4-yl)-2-(methylcarbonyloxyimino)acetamido]-3-vinyl-cephem-4-carboxylic acid of formula (I), in the form of a crystalline salt and use thereof, e.g. in the preparation of pure cefdinir. In another aspect this invention relates to the compound of formula (I) in the form of a salt, optionally in crystalline form, wherein the salt is selected from the group consisting of phosphate, hydrogen phosphate, mesylate, tosylate, sulfate, hydrogen sulfate and sulfamate.
    Type: Grant
    Filed: June 21, 2007
    Date of Patent: November 2, 2010
    Assignee: Sandoz AG
    Inventors: Peter Kremminger, Siegfried Wolf, Johannes Ludescher
  • Patent number: 7741478
    Abstract: Compounds of general formula (II), wherein R1 represents R4 represents hydrogen or —CHO group, R5 represents hydrogen or trityl, R2 represents hydrogen or methoxy group, R3 represents —CH?CH2 or and M represents a dialkyl or dicycloalkyl ethylenediamine group selected from N,N?-diisobutylethylenediamine, N,N?-dicyclohexylethylenediamine, and N,N?-dicyclopentylethylenediamine, are useful in a process to make cephalosporin antibiotics of formula (I) wherein R represents hydrogen or pharmaceutically acceptable esters or alkali metals salts.
    Type: Grant
    Filed: July 4, 2005
    Date of Patent: June 22, 2010
    Assignee: Orchid Chemicals & Pharmaceuticals Limited
    Inventors: Udayampalayam Palanisamy Senthilkumar, Venu Sanjeevi Lakshmipathi, Gnanaprakasam Andrew, Ramasubbu Chandrasekaran, Dindigala Nagender Rao, Gaddam Om Reddy
  • Patent number: 7728127
    Abstract: This invention provides cross-linked glycopeptide-cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using such compounds; and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: August 24, 2007
    Date of Patent: June 1, 2010
    Assignee: Theravance, Inc.
    Inventors: Paul R. Fatheree, Martin S. Linsell, Daniel Marquess, S. Derek Turner
  • Patent number: 7728126
    Abstract: Method for purifying 7?-methoxy-cephalosporins containing as impurity the corresponding 7?-methylthio analogue, which is transformed into its methoxy analogue by treatment with a halogenating agent in methanol. In this way the complete conversion of the sulphurated impurity into the corresponding methoxy analogue is obtained.
    Type: Grant
    Filed: August 17, 2006
    Date of Patent: June 1, 2010
    Assignee: ACS DOBFAR S.p.A.
    Inventors: Giovanni Fogliato, Marco Forzatti, Maurizio Zenoni
  • Publication number: 20100009954
    Abstract: Inhibitors of the enzyme beta-lactamase are provided. The compounds are adapted to inhibit beta-lactamase as produced by beta-lactam resistant bacterial strains. Methods of treatment of beta-lactam resistant bacterial infections in patients are provided.
    Type: Application
    Filed: May 11, 2009
    Publication date: January 14, 2010
    Inventors: John D. Buynak, Anjaneyulu Sheri, Sundar Ram Reddy Pagadala
  • Patent number: 7615631
    Abstract: Crystalline acetonitrile solvate of cefuroxime acid, useful for preparing the antibiotic cefuroxime sodium salt.
    Type: Grant
    Filed: April 18, 2006
    Date of Patent: November 10, 2009
    Assignee: ACS Dobfar S.p.A.
    Inventors: Maurizio Zenoni, Angelo Giovanni Cattaneo
  • Patent number: 7592447
    Abstract: A process for the production of intermediates having a formula IA that can be used for the synthesis of cephalosporins, such as cefepime of formula V. The intermediates of formula IA are produced by desilyation of a compound of formula II wherein R4 is a silyl-protecting group, with a protic solvent to obtain a compound of formula III, and reacting the compound of formula III with an organic base of formula IV wherein R2 and R3 together represent a C4-alkylene group, and with the adjacent nitrogen atom form a saturated 5-membered heterocycle, and R1 represents a methyl group, to obtain the compound of formula 1A.
    Type: Grant
    Filed: December 22, 2004
    Date of Patent: September 22, 2009
    Assignee: Sandoz AG
    Inventors: Johannes Ludescher, Hubert Sturm, Katja Vorndran
  • Publication number: 20090233899
    Abstract: A novel crystalline modification of cefuroximaxetil (?-modification), pharmaceutical compositions containing this modification, and their use.
    Type: Application
    Filed: October 23, 2008
    Publication date: September 17, 2009
    Applicant: Gruenenthal GmbH
    Inventor: Andreas Fischer